SCA
CRL icon

Stuart Chaussee & Associates’s Charles River Laboratories CRL Stock Holding History

Stuart Chaussee & Associates’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-20
Closed -$4.04K – 134
2023
Q1 		$4.04K Hold
20
– – ﹤0.01% 126
2022
Q4 		$4.36K Hold
20
– – ﹤0.01% 134
2022
Q3 		$4K Hold
20
– – 0.01% 128
2022
Q2 		$4K Hold
20
– – 0.01% 133
2022
Q1 		$6K Sell
20
-19
-49% -$5.86K ﹤0.01% 139
2021
Q4 		$15K Hold
39
– – 0.01% 100
2021
Q3 		$16K Hold
39
– – 0.02% 79
2021
Q2 		$14K Hold
39
– – 0.01% 92
2021
Q1 		$11K Buy
+39
New +$10.8K ﹤0.01% 116

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Stuart Chaussee & Associates's CRL Position: Q2 2023 in Review

Stuart Chaussee & Associates sold out of Charles River Laboratories (CRL) in Q2 2023, closing a stake of 20 shares — an estimated $4.04K sold.

Stuart Chaussee & Associates first reported a position in CRL in Q1 2021 and held it in 9 quarters. The position peaked at $16K in Q3 2021. 612 funds tracked by Wall St. Rank hold CRL as of Q2 2023.

  • Stuart Chaussee & Associates reported no remaining Charles River Laboratories position as of Q2 2023 after selling out during the quarter.
  • Stuart Chaussee & Associates sold 20 Charles River Laboratories shares in Q2 2023, an estimated $4.04K.
  • Stuart Chaussee & Associates first reported a position in Charles River Laboratories in Q1 2021 and held it in 9 quarters.
  • Stuart Chaussee & Associates's Charles River Laboratories position peaked at $16K in Q3 2021.
  • 612 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2023.

Based on Stuart Chaussee & Associates's 13F filing for Q2 2023, filed 4 Aug 2023.